Therefore, there is a high degree of expectation in combination therapy of BRAF inhibitor and anti-EGFR antigen, etc. for BRAF mutation-positive colon cancer, and the outcome of future clinical trials is eagerly expected. This evidence concerns the gene EGFR and malignant colon neoplasm.